Allergan files INDs for Peplin's topical treatment
25 March, 2004 by Renate KrellePeplin Biotech (ASX: PEP) today announced the filing of three separate Investigational New Drug (IND) applications with the US Food and Drug Administration for a topical formulation of its lead compound PEP005.
Select Vaccines signs agreement to develop Hep C test
25 March, 2004 by Melissa TrudingerSelect Vaccines (ASX: SLT) has signed a materials transfer agreement (MTA) with a multinational biotechnology company to access materials it will use to accelerate the development of its hepatitis C rapid diagnostic test.
Prana appoints US analyst to board
25 March, 2004 by Melissa TrudingerMelbourne biotech company Prana Biotechnology (ASX: PBT) has appointed leading US biotech analyst Dr Jonas Alsenas to its board of directors.
Bracks bans GMHT canola until 2008
25 March, 2004 by Graeme O'NeillThe Victorian Government has announced a four-year, legislated moratorium on commercial cropping of genetically modified herbicide-tolerant (GMHT) canola.
Biota signs new flu diagnostic agreement
24 March, 2004 by Melissa TrudingerBiota (ASX:BTA) has signed a new agreement with its US-based flu diagnostics partner Thermo Electron giving it a profit share in a second influenza diagnostic kit, FLU OIA A/B.
GM banned in WA
23 March, 2004 by Iain ScottWestern Australian premier Geoff Gallop has announced that genetically modified food crops will not be grown in the state.
Psivida subsidiary signs manufacturing deal
23 March, 2004 by Melissa TrudingerPsiMedica, the UK subsidiary of Perth-based nanotechnology company Psivida (ASX:PSD), has signed a three-year manufacturing agreement with nuclear pharmaceuticals company Auriga Medical as it gears up to start Phase II clinical trials of its BioSilicon-based brachytherapy product in Singapore later this year.
Axon accepts takeover bid
23 March, 2004 by Renate KrelleMicroarray and cellular screening company Axon Instruments (ASX:AXN) has accepted a friendly takeover offer from California-based Molecular Diagnostics.
Sydney firm develops new DNA ID method
23 March, 2004 by Melissa TrudingerSydney-based company Human Genetic Signatures (HGS) has developed a new method for identifying DNA methylation patterns -- an epigenetic phenomenon thought to play a role in ageing and disease.
Amrad reveals share buyback scheme
22 March, 2004 by Melissa TrudingerAmrad (ASX:AML) has announced plans to buy back up to 10 per cent of its shares over the next 12 months, at a cost of around AUD$9 million at the current share price of AUD$0.69.
GM crops: Australia waits for the world
19 March, 2004 by Graeme O'NeillMonday is M-Day for Victoria: will the Bracks government end its 12-month, voluntary moratorium on commercial cropping of genetically modified canola, imposed in May last year?
Greenpeace accuses CSIRO of suppressing GE reports
17 March, 2004 by Graeme O'NeillGreenpeace Australia-Pacific has accused the CSIRO of suppressing several reports on environmental risks associated with genetically engineered crops, and alleged the Office of the Gene Technology Regulator was failing to acknowledge and assess “serious hazards” before granting GE crop licenses.
US partnership to speed up corn genome sequencing
17 March, 2004 by Staff WritersBiotechnology companies have agreed to make their data public in a bid to advance a project to decoding the genetic structure of corn several years ahead of schedule.
Tissue Therapies closes IPO early, oversubscribed
16 March, 2004 by Renate KrelleBrisbane-based Tissue Therapies looks set to list on the ASX as early as this Friday, after closing its AUD$3.5 million initial public offering two weeks early, as the offer was oversubscribed.
New research shows how rust robs plant cells
16 March, 2004 by Graeme O'NeillCSIRO Plant Industry researchers have identified the molecular skeleton key that allows rust fungi -- ubiquitous pathogens of cereal and horticultural crops around the world -- to burgle plant cells.
